Importantly, at the time of comparing the different treated groups, significant differences were found regarding mice body weight changes, tumour volume evolution and survival average, the best overall outcome always being obtained with the anti-PD-1/TMZ combined treatment in IMS, which proved clearly better than either monotherapy alone. This evidence concerns the gene PDCD1 and neoplasm.